Valuation: Altimmune, Inc.

Market Cap 636M 555M 522M 476M 892M 60.94B 893M 6.26B 2.41B 31.04B 2.39B 2.34B 100B P/E 2026 *
-5.58x
P/E 2027 * -4.99x
Enterprise Value 196M 171M 161M 146M 274M 18.74B 275M 1.92B 741M 9.55B 735M 718M 30.78B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.62%
Current month+5.14%
1 month+10.85%
3 months+21.11%
6 months-2.10%
Current year-9.42%
1 week 3.18
Extreme 3.18
3.35
1 month 3.02
Extreme 3.02
3.55
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 31/12/2025
Director of Finance/CFO 70 10/11/2024
Chief Tech/Sci/R&D Officer - 30/04/2025
Director TitleAgeSince
Director/Board Member 58 31/08/2003
Chairman 78 31/12/2017
Director/Board Member 76 30/06/2012
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/26 Exercice

Executive/Senior Manager

54,826 0.0282%
13/08/26 Buy

Chief Executive Officer

15,000 0.0077%
31/07/26 Free

Chief Financial Officer

1,753 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%0.00%-13.49%+21.11% 632M
+4.98%+11.06%+54.45%+109.45% 70.88B
-0.39%+1.66%+38.84%+78.01% 62.49B
+5.26%+12.77%+40.29%+26.34% 26.34B
+0.83%-6.50%-16.41%+374.14% 26.21B
+2.02%+1.31%+1.85%-9.77% 24.13B
0.00%+8.03%+25.03%-13.74% 20.72B
-2.54%-10.16%+149.64%+313.93% 15.69B
-1.95%+1.96%+42.69%+166.02% 14.46B
-5.32%-3.70%-10.53%+808.60% 14.24B
Average +0.35%+1.70%+31.23%+187.41% 27.58B
Weighted average by Cap. +1.43%+2.89%+37.30%+150.35%

Financials

2026 *2027 *
Net sales - -
Net income -100M -87.66M -82.51M -75.16M -141M -9.63B -141M -988M -381M -4.9B -377M -369M -15.81B -123M -107M -101M -92.11M -173M -11.8B -173M -1.21B -467M -6.01B -463M -452M -19.38B
Net Debt -440M -384M -362M -329M -618M -42.2B -619M -4.33B -1.67B -21.5B -1.65B -1.62B -69.32B -332M -289M -272M -248M -465M -31.78B -466M -3.26B -1.26B -16.19B -1.25B -1.22B -52.2B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
21/09/26 US$3.270 +0.62% 3,515,229
18/09/26 US$3.250 +0.31% 12,176,850
17/09/26 US$3.240 0.00% 3,457,393
16/09/26 US$3.240 +0.31% 3,331,820
15/09/26 US$3.230 -2.12% 2,339,114
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.270USD
Average target price
17.22USD
Spread / Average Target
+426.67%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!